{
  "hypothesis": "h157",
  "title": "Autoimmune Drug Class Analysis",
  "summary": "DMARDs achieve 75.4% precision for autoimmune diseases. Biologics (anti-TNF, IL inhibitors) rarely appear due to training data sparsity.",
  "key_findings": {
    "dmard_precision": "75.4% \u00b1 4.7% (5-seed, n=21.6/seed)",
    "anti_tnf_precision": "N/A - 0 predictions in top-30",
    "il_inhibitor_precision": "N/A - 0 predictions in top-30",
    "jak_inhibitor_precision": "0.0% (n=0.8/seed)"
  },
  "root_cause": {
    "issue": "Biologics have extremely low training frequency",
    "adalimumab": "freq=4 (vs methotrexate=275)",
    "infliximab": "freq=6",
    "etanercept": "freq=9",
    "most_il_inhibitors": "freq=0-2",
    "dmards": "freq=56-275 (methotrexate=275, cyclosporine=232, azathioprine=120)"
  },
  "drug_class_frequencies": {
    "methotrexate": 275,
    "cyclosporine": 232,
    "azathioprine": 120,
    "hydroxychloroquine": 58,
    "sulfasalazine": 56,
    "etanercept": 9,
    "tacrolimus": 8,
    "infliximab": 6,
    "leflunomide": 5,
    "adalimumab": 4,
    "tocilizumab": 2,
    "secukinumab": 2,
    "ustekinumab": 1,
    "golimumab": 1
  },
  "production_recommendation": "Add DMARD + rank<=10 as GOLDEN tier for autoimmune (75% precision). Biologics cannot be rescued - data sparsity is fundamental.",
  "success": true
}